SciVida assisted a global specialty biopharmaceutical company focused on rare disease in its due diligence of a product it was considering in-licensing, elucidating potential pricing elasticity for the product as well as market access dynamics.

Situation

Our client, an established company in the rare disease space, was considering diversifying its portfolio through in-licensing of a novel asset indicated for a rare disease that had no approved treatments. The client wanted to understand pricing and market access potential for the new asset and how dynamics were impacted by the emergence of a key competitor that was expected to be first to market.

SciVida’s Approach

SciVida gathered and reviewed the client’s materials, and, given the imminent need for insights on which to base a go/no-go decision, our team jumped right into a working session with the core client team to identify and prioritize the key business questions and plan to generate the requisite insights, including a combination of desk research, third-party data analysis, and focused primary research.

Our team conducted secondary research to fill information gaps necessary to support the focused primary research with payers. In a short time, SciVida was able to gather critical insights on payer perceptions of the disease, the asset, and the key competitor; anticipated coverage and handling, including coverage considerations; and product benchmarks for pricing, price expectations, and price sensitivity.

Our due diligence support also included a risk analysis of value assessment by Institute for Clinical and Economic Review (ICER).

We synthesized the insights from our primary and secondary research and ICER risk analysis into key takeaways and considerations to support the client’s go/no-go decision.

SciVida assisted an early-stage biotech company in articulating the market potential and commercial story for its lead product candidate for engaging with external stakeholders in prospective partnership/investor discussions.

Situation

Our client, an emerging biotech with several assets in preclinical and clinical development, was nearing Phase 2 on its lead candidate and preparing to engage in partner/investor discussions. The asset was an innovative and targeted disease-modifying therapy for a historically mismanaged condition, and the client needed help explaining the complex disease landscape and crafting a compelling commercial story regarding the product’s potential value.

SciVida’s Approach

Our team began by facilitating a brainstorming workshop with the client’s leadership team to align on key requirements for the investor presentation as well as strategic imperatives within key areas to support commercial success.

SciVida combined output from the workshop with all previously completed relevant work and collaborated closely with the client to align on key needs for the investor presentation. The document was designed to include disease background, current treatment landscape, key unmet needs, the market size and opportunity, the asset’s value proposition, and a winning strategy for the client centered around their priority areas of regulatory approval, competitive differentiation, and market access.

We socialized a detailed outline with executives from the client team, refined the structure, and then developed the presentation.

Finally, our team iterated with the client’s senior leaders and board of directors to finalize the presentation, which was then immediately shared with prospective partners and investors.